Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series.

Drug Pricing 77

Drug Pricing Biosimilars 77

Drug Channels

MAY 21, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m.

Drug Pricing 52

Drug Pricing 52

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Friday, September 24, 2021, from 12:00 p.m.

Drug Pricing 74

Drug Pricing Biosimilars Hospitals 74

Drug Channels

MARCH 31, 2023

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Time for the Drug Channels annual reality check on drug pricing. d/b/a Drug Channels Institute. healthcare expenditures.

Drug Pricing 75

Drug Pricing 75

Drug Channels

DECEMBER 5, 2023

The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drug pricing system. to 1:30 p.m.

Drug Pricing 84

Drug Pricing Hospitals 84

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Drug Channels

APRIL 5, 2024

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs. It's time for Drug Channels ’ annual reality check on U.S. drug pricing.

Drug Pricing 68

Drug Pricing 68

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The Outlook 2022 marks our third annual outlook webinar.

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Biosimilars 52

Drug Channels

JUNE 22, 2022

See The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards. In the video below, I discuss how generic drug pricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. d/b/a Drug Channels Institute.

Drug Pricing 58

Drug Pricing 58

Drug Channels

JUNE 1, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest live video webinar: Drug Channels Update: 340B Controversies and Outlook. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Friday, June 25, 2021 (12:00 p.m.

Drug Pricing 52

Drug Pricing 52

Drug Channels

JULY 12, 2024

Gavin discusses the three key reasons for duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. To learn more, register for Kalderos’ August 21, 2024, webinar: Revolutionizing Government Discount Programs: Why Traditional Methods Fail. Read on for Gavin’s insights.

Drug Pricing 94

Drug Pricing 94

Drug Channels

AUGUST 21, 2020

As regular readers know, I believe the 340B Drug Pricing Program needs to evolve into a more transparent, properly regulated program. To help the industry learn more about 340B rebates, Kalderos is sponsoring a live video webinar: Evolving 340B: Moving from Discounts to Rebates. to 1:00 p.m.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 23, 2021

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year.

Drug Pricing 52

Drug Pricing 52

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

OCTOBER 10, 2023

ASBM Statement on Announcement of Medicare Drug Price-Setting List On August 29th, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed into law last year.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Drug Channels

MARCH 21, 2024

How will the most consequential change in federal drug pricing policy affect drug pricing? Find out during Drug Channel Implications of the Inflation Reduction Act , a new live video webinar with Adam J. Click here to learn more and reserve your spot at the April 5 webinar.

Drug Pricing 75

Drug Pricing 75

Safe Biologics

SEPTEMBER 12, 2023

ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Drug Channels

DECEMBER 8, 2020

When Americans complains about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel. Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices.

Drug Pricing 52

Drug Pricing 52

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Drug Channels

MARCH 25, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. When Americans complain about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed.

Drug Pricing 52

Drug Pricing 52

Drug Channels

JULY 28, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. That’s why I refer to them as drug pricing flat earthers (#DPFE).

Drug Pricing 89

Drug Pricing Pharmaceutical Manufacturing 89

Safe Biologics

FEBRUARY 1, 2024

In January, the Generics and Biosimilars Initiative (GaBI) published a whitepaper entitled “ Medicare Drug Price Negotiations: Impact on Healthcare Development and Patient Access to Medicines” The paper’s content is drawn from a webinar on the same topic hosted by ASBM and GaBI on July 26, 2023.

Drug Pricing 100

Drug Pricing Biosimilars 100

Drug Channels

JUNE 4, 2024

Find out during The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Click here to learn more and reserve your spot at the June 21 webinar. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Hospitals 80

Hospitals Physician Offices Drug Pricing 80

Drug Channels

JUNE 21, 2024

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. The webinar begins at 12:00 PM ET. Click here to see the original post from March 2024.

Drug Pricing 73

Drug Pricing 73

Drug Channels

MARCH 12, 2024

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before April 7, 2024. Pharmacies and Pharmacy Benefit Managers. For 2023, DCI estimates that U.S. to 1:30 p.m.

Drug Pricing 81

Drug Pricing 81

Drug Channels

APRIL 1, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers.

Drug Pricing 87

Drug Pricing Hospitals 87

Drug Channels

NOVEMBER 25, 2024

drug prices really higher than other countries? Coming soon: Drug Channels Outlook 2025 , our biggest live video webinar of the year. In this issue: Intriguing data on how employers oversee their PBMs State Medicaid programs carve out PBMs—and get a 340B windfall Are U.S.

Drug Pricing 59

Drug Pricing 59

Drug Channels

OCTOBER 12, 2020

Informa Connect-CBI’s 6th Edition Drug Pricing Transparency Congress. November 16-17, 2020 | Virtual Event www.informaconnect.com/drug-pricing-transparency. Drug Channels Readers: View the complete agenda and register today. Be sure to use your exclusive promo DRUG30 to save $300 *.

Drug Pricing 40

Drug Pricing 40

Safe Biologics

DECEMBER 3, 2023

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars. Learn more about ACR Convergence 2023 here.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Big Molecule Watch

JULY 18, 2023

On June 30, 2023, the Centers for Medicare & Medicaid Services (CMS) released its updated final program guidance covering the Inflation Reduction Act’s Medicare Drug Price Negotiation Program for the first round of negotiations, which will occur during 2023 and 2024 and result in prices that will be effective beginning in 2026.

Drug Pricing 40

Drug Pricing 40

Drug Channels

SEPTEMBER 29, 2023

According to Kalderos, at least 5% of commercial rebates are paid for prescriptions that also have discounts under the 340B Drug Pricing Program. To learn about Kalderos’ Commercial Discount Monitoring solution, close your eyes and slip away with Micah at his free webinar on November 1, 2023, at 2:00 p.m.

Drug Pricing 81

Drug Pricing 81

Drug Channels

JUNE 13, 2023

When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. However, some companies had net price gains. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices.

Drug Pricing 81

Drug Pricing Pharmaceutical Manufacturing 81

Drug Channels

DECEMBER 15, 2023

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. The difference between list prices and discounted 340B purchases also grew, to $52.3 billion (+$2.6

Drug Pricing 81

Drug Pricing Hospitals 81

Safe Biologics

NOVEMBER 12, 2023

View the full webinar here or watch individual segments linked below. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. Thanks to the IRA’s price controls, medical marvels like Keytruda will now be even more difficult to achieve.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Drug Channels

JULY 12, 2022

Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. d/b/a Drug Channels Institute. Read on for details and my commentary below.

Drug Pricing 87

Drug Pricing Hospitals 87

Big Molecule Watch

OCTOBER 2, 2023

Ohio, Judge Newman) issued the first substantive order addressing legal challenges to the Drug Price Negotiation Program of the Inflation Reduction Act. New Complaint by Novo Nordisk Also on Friday, Novo filed a new Complaint challenging the Drug Price Negotiation Program and CMS’s actions in implementing it.

Drug Pricing 64

Drug Pricing Documentation 64